V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004462 | 330002166 | 1.76 | 136 | Palliative (P) | 2017-12-17 | 2017-12-22 | DABRAFENIB | 02 | N | 330018043 | IVA |
| 330004463 | 330002166 | 1.6 | 65.4 | Curative (C) | 2014-10-11 | 2015-01-15 | Bevacizumab + CARBOPLATIN + PACLITAXEL | null | null | 330018043 | FCR |
| 330004464 | 330002166 | 0 | 74 | Palliative (P) | 2013-03-05 | 2013-03-06 | ALL UKALL2011 Ind B Sht Dex (PAsp) | N | N | 330018043 | CARBOPLATIN + VINCRISTINE |
| 330004465 | 330002166 | 1.57 | null | null | null | 2017-01-29 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | null | null | 330018043 | EDP + MITOTANE |
| 330004466 | 330002166 | null | 54.9 | null | null | 2016-02-02 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | null | null | 330018043 | AFATINIB |
| 330004467 | 330002166 | null | 57.8 | Not known (9) | 2015-07-11 | 2015-07-17 | FCR Oral - Cycle 1 | N | N | 330018043 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330004468 | 330002167 | 1.79 | 73.2 | Disease modification (D) | 2017-11-12 | 2017-11-12 | Cisplatin+Doxorubicin+Etoposide 21d | 2 | N | 330018084 | VIDE |
| 330004469 | 330002168 | 1.77 | 86.6 | null | 2013-03-23 | 2013-04-24 | ALL UKALL2011 Maintenance A4 | 02 | N | 330018086 | MELPHALAN |
| 330004470 | 330002168 | null | 68.8 | Palliative (P) | 2016-08-18 | 2016-08-24 | CHOP - 21 days | N | Y | 330018086 | UKALL60+ |
| 330004471 | 330002169 | 1.63 | 10.4 | Curative (C) | 2018-08-06 | 2018-08-09 | VIDE | Y | N | 330018106 | RUXOLITINIB |
| 330004472 | 330002169 | 0 | 91.6 | Palliative (P) | 2013-09-06 | 2013-09-08 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | null | 330018106 | CISPLATIN + FLUOROURACIL + RT |
| 330004473 | 330009904 | 1.8 | 91.6 | Palliative (P) | 2014-10-23 | 2014-10-24 | Melphalan IV High dose | Y | Y | 330018141 | CYTARABINE |
| 330004474 | 330009904 | 1.56 | 114 | Disease modification (D) | 2018-01-22 | 2018-01-27 | PEMBROLIZUMAB | N | N | 330018141 | AML17 TRIAL |
| 330004475 | 330009904 | 1.72 | 73 | Palliative (P) | 2013-02-27 | 2013-03-15 | Carboplatin + Pemetrexed | N | N | 330018141 | CARBOPLATIN + RT |
| 330004476 | 330002170 | 1.82 | 68.999 | Curative (C) | null | 2014-04-02 | DOXORUBICIN + IFOSFAMIDE | N | N | 330018153 | DE-ESCALATE TRIAL |
| 330004477 | 330002170 | null | null | 4 | 2015-01-12 | 2015-02-15 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330018153 | CISPLATIN + DOCETAXEL |
| 330004478 | 330002170 | 1.6 | 96.9 | Curative (C) | null | 2015-04-29 | IPILIMUMAB + NIVOLUMAB | N | N | 330018153 | FLUOROURACIL + MITOMYCIN + RT |
| 330004479 | 330002171 | 1.6 | 63.2 | Palliative (P) | 2018-05-22 | 2018-05-23 | Methotrexate + Folinic acid | N | N | 330018182 | IPILIMUMAB + NIVOLUMAB |
| 330004480 | 330007200 | 1.6 | 66.9 | Palliative (P) | 2018-05-03 | 2018-05-17 | CHOP R - 21 days | N | N | 330018216 | AML16 TRIAL |
| 330004481 | 330007200 | 1.7 | 91.3 | Palliative (P) | 2016-05-15 | 2016-05-19 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330018216 | METHOTREXATE |
| 330004482 | 330011412 | 1.65 | 76.1 | null | 2017-02-17 | 2017-02-17 | Bevacizumab+Carbo+Gemcitabine | N | N | 330018245 | CARBOPLATIN + DOCETAXEL |
| 330004483 | 330002172 | 1.65 | 99.3 | Curative (C) | 2013-08-07 | 2013-08-07 | CAPECITABINE + CARBOPLATIN + Cetuximab | 2 | N | 330018255 | TOPOTECAN |
| 330004484 | 330002172 | 1.6 | 90.9 | Curative (C) | 2013-08-09 | 2013-08-09 | PEMBROLIZUMAB | 01 | N | 330018255 | CHLORAMBUCIL + RITUXIMAB |
| 330004485 | 330002173 | null | null | Curative (C) | 2014-11-11 | 2014-11-12 | Doxorubicin + Olaratumab | N | N | 330018266 | PAZOPANIB |
| 330004486 | 330002173 | 1.65 | null | Palliative (P) | 2018-02-11 | 2018-02-18 | PACLITAXEL | 02 | N | 330018266 | CARBOPLATIN + EPIRUBICIN + FLUOROURACIL |
| 330004488 | 330002175 | 1.67 | 44.5 | Curative (C) | 2017-07-30 | 2017-07-31 | Ipilimumab | 2 | N | 330018276 | CAPECITABINE |
| 330004489 | 330002175 | 1.83 | 79 | Curative (C) | 2014-12-14 | 2014-12-19 | Cytarabine Low Dose | N | N | 330018276 | DOXORUBICIN + IFOSFAMIDE |
| 330004490 | 330002175 | 1.78 | 71 | Palliative (P) | 2013-08-29 | 2013-08-29 | Vinorelbine (oral) | N | N | 330018276 | TVD |
| 330004491 | 330002176 | null | 57.9 | Curative (C) | 2018-02-28 | 2018-03-09 | Doxorubicin + Olaratumab | N | N | 330018332 | FLUOROURACIL + MITOMYCIN + RT |
| 330004492 | 330002176 | 1.81 | 83.8 | Palliative (P) | 2016-04-28 | 2016-05-02 | Azacitidine | N | N | 330018332 | BENDAMUSTINE |
| 330004493 | 330002177 | 1.67 | null | Not known (9) | 2013-06-04 | 2013-06-05 | OST Euramos 1 Closed Trial - M | 02 | N | 330018358 | VINBLASTINE |
| 330004494 | 330002178 | 1.55 | 94.4 | Palliative (P) | 2016-04-02 | 2016-04-02 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330018368 | CARBOPLATIN + RT |
| 330004495 | 330007205 | 1.72 | 110 | Adjuvant (A) | 2016-11-22 | 2016-11-22 | NB BEACON Temozolomide Bevacizumab | 02 | N | 330018380 | CISPLATIN + FLUOROURACIL + RT |
| 330004496 | 330002179 | 1.68 | 107.9 | Palliative (P) | null | 2017-09-08 | METHOTREXATE | N | N | 330018386 | ABIRATERONE |
| 330004497 | 330002179 | 1.67 | 103 | Palliative (P) | 2015-10-28 | 2015-11-12 | Chlorambucil | N | N | 330018386 | FEC |
| 330004498 | 330002179 | 1.84 | 81.5 | Palliative (P) | null | 2017-05-12 | Chlorambucil + Pred + Rituximab | N | N | 330018386 | CAPECITABINE + IRINOTECAN |
| 330004499 | 330002180 | 1.8 | 65.8 | Disease modification (D) | 2013-09-02 | 2013-09-03 | CARBOPLATIN + RT | N | N | 330018398 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330004500 | 330002180 | 1.68 | 84 | Adjuvant (A) | 2016-03-11 | 2016-03-11 | Temozolomide + RT | 02 | null | 330018398 | DE-ESCALATE TRIAL |
| 330004501 | 330002181 | 1.76 | 58.4 | Disease modification (D) | 2014-05-13 | 2014-05-13 | ALL UKALL2011 Maintenance B1 | 02 | null | 330018404 | OXALIPLATIN + MDG |
| 330004502 | 330002181 | 0 | 0 | Curative (C) | 2017-07-20 | 2017-07-20 | MABCUTE TRIAL | 02 | N | 330018404 | FLUOROURACIL |
| 330004503 | 330002182 | null | null | null | 2016-02-07 | 2016-02-12 | Sunitinib | 02 | Y | 330018437 | CETUXIMAB + CISPLATIN + FU |
| 330004504 | 330002183 | 1.58 | 63.2 | Palliative (P) | null | 2017-03-11 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | null | null | 330018444 | FLUOROURACIL + MITOMYCIN + RT |
| 330004505 | 330002184 | 1.77 | null | Palliative (P) | 2016-06-14 | 2016-06-29 | DOXORUBICIN + IFOSFAMIDE | null | null | 330018466 | CISPLATIN + FLUOROURACIL + RT |
| 330004506 | 330002185 | 1.8 | 22.1 | Palliative (P) | 2015-03-03 | 2015-03-28 | Docetaxel | N | null | 330018484 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330004507 | 330002186 | 1.63 | 59.3 | Disease modification (D) | 2016-09-09 | 2016-09-26 | IPILIMUMAB + NIVOLUMAB | N | N | 330018485 | CAV |
| 330004508 | 330007209 | 1.6 | null | Adjuvant (A) | 2014-12-20 | 2015-01-24 | FLAG + Idarubicin | null | N | 330018501 | CARBOPLATIN + VINCRISTINE |
| 330004509 | 330007209 | 1.59 | 80.05 | null | 2015-08-02 | 2015-11-02 | VIDE | N | N | 330018501 | FEC |
| 330004510 | 330002187 | null | 62.4 | Neo-adjuvant (N) | 2015-09-21 | 2015-09-25 | EP | N | N | 330018511 | OXALIPLATIN + MDG |
| 330004511 | 330002188 | null | 97.5 | Adjuvant (A) | 2015-03-16 | 2015-03-24 | CHOP R - 21 days | N | N | 330018514 | AML17 TRIAL |
| 330004512 | 330002189 | 0 | 89 | Palliative (P) | 2013-09-06 | 2013-09-09 | Enzalutamide | 02 | N | 330018515 | AZACITIDINE |